Document is current
Any future updates will be listed below
-
Authors
Felten, Renaud https://orcid.org/0000-0002-4951-4032
Toussirot, Eric https://orcid.org/0000-0002-6228-1464
- License Information
-
More Information
Article History
Accepted: 26 September 2023
First Online: 30 October 2023
Declarations
:
: There is no funding related to this work.
: T.E. has no conflict of interest to declare related to this review article. R.F.: honoraria/consulting fees from: AbbVie, BMS, Lilly, Nordic, Novartis, MEDAC, MSD, Pfizer and UCB. Advisory boards: AbbVie, BMS, Janssen, Galápagos, Novartis and UCB. Grant for research: None.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: RF and ET equally contributed to the work.
